Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership

Proprietary Synthetic Polynucleotide Platform Accelerates Non-Viral, Footprint-Free Induced Pluripotent Stem Cell Generation Amid Surging Commercialization of iPSC Therapies in JapanSEATTLE, June 16, ...
News Medical

New directions in cell therapy: iPSC platforms and in vivo reprogramming

Induced pluripotent stem cells (iPSCs) are derived from adult cells, such as skin or blood cells, which have been “reprogrammed” back to a stem-cell-like state. This transformation grants them the ...

Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd

Pluristyx Inc., the leader in advanced induced pluripotent stem cell (iPSC) technologies, announces today the Initial Close of their Series A financing led by a global Fortune 500 company along with ...
The Scientist

New iPSC Reprogramming Method Uses Proteins Instead of DNA

Researchers have attained the holy grail of cellular reprogramming: inducing pluripotency without using any DNA-based materials. Using only a cocktail of purified proteins and a chemical additive, ...
News Medical

iXCells Biotechnologies reaches iPSC line delivery milestone in collaboration with global biotechnology company

iXCells Biotechnologies USA, Inc. ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent ...